Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Bradley J Langford, Miranda So, Sumit Raybardhan, Valerie Leung, Duncan Westwood, Derek R MacFadden, Jean-Paul R Soucy, Nick Daneman, Bradley J Langford, Miranda So, Sumit Raybardhan, Valerie Leung, Duncan Westwood, Derek R MacFadden, Jean-Paul R Soucy, Nick Daneman

Abstract

Background: Bacterial co-pathogens are commonly identified in viral respiratory infections and are important causes of morbidity and mortality. The prevalence of bacterial infection in patients infected with SARS-CoV-2 is not well understood.

Aims: To determine the prevalence of bacterial co-infection (at presentation) and secondary infection (after presentation) in patients with COVID-19.

Sources: We performed a systematic search of MEDLINE, OVID Epub and EMBASE databases for English language literature from 2019 to April 16, 2020. Studies were included if they (a) evaluated patients with confirmed COVID-19 and (b) reported the prevalence of acute bacterial infection.

Content: Data were extracted by a single reviewer and cross-checked by a second reviewer. The main outcome was the proportion of COVID-19 patients with an acute bacterial infection. Any bacteria detected from non-respiratory-tract or non-bloodstream sources were excluded. Of 1308 studies screened, 24 were eligible and included in the rapid review representing 3338 patients with COVID-19 evaluated for acute bacterial infection. In the meta-analysis, bacterial co-infection (estimated on presentation) was identified in 3.5% of patients (95%CI 0.4-6.7%) and secondary bacterial infection in 14.3% of patients (95%CI 9.6-18.9%). The overall proportion of COVID-19 patients with bacterial infection was 6.9% (95%CI 4.3-9.5%). Bacterial infection was more common in critically ill patients (8.1%, 95%CI 2.3-13.8%). The majority of patients with COVID-19 received antibiotics (71.9%, 95%CI 56.1 to 87.7%).

Implications: Bacterial co-infection is relatively infrequent in hospitalized patients with COVID-19. The majority of these patients may not require empirical antibacterial treatment.

Keywords: Bacterial infections; COVID-19; Co-infection; Living review; Secondary infection.

Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Fig. 1
Fig. 1
Study flow diagram.
Fig. 2
Fig. 2
Percentage of patients with COVID-19 and bacterial co-infection or secondary infection.
Fig. 3
Fig. 3
Percentage of patients with COVID-19 and bacterial infection stratified by estimated severity of illness.

References

    1. Esper F.P., Spahlinger T., Zhou L. Rate and influence of respiratory virus co-infection on pandemic (H1N1) influenza disease. J Infect. 2011;63:260–266.
    1. Klein E.Y., Monteforte B., Gupta A., Jiang W., May L., Hsieh Y.-H., et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016;10:394–403.
    1. Rice T.W., Rubinson L., Uyeki T.M., Vaughn F.L., John B.B., Miller R.R., et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 2012;40:1487–1498.
    1. Shah N.S., Greenberg J.A., McNulty M.C., Gregg K.S., Riddell J., Mangino J.E., et al. Bacterial and viral co-infections complicating severe influenza: incidence and impact among 507 US patients, 2013–14. J Clin Virol. 2016;80:12–19.
    1. Martín-Loeches I., Sanchez-Corral A., Diaz E., Granada R.M., Zaragoza R., Villavicencio C., et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest. 2011;139:555–562.
    1. Huttner B., Catho G., Pano-Pardo J.R., Pulcini C., Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26:808–810.
    1. Cox M.J., Loman N., Bogaert D., O’Grady J. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020 S2666524720300094.
    1. World Health Organization . World Health Organization; Geneva, Switzerland: 2020. Clinical management of COVID-19 interim guidance [Internet] Available from:
    1. Alhazzani W., Møller M.H., Arabi Y.M., Loeb M., Gong M.N., Fan E., et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) Crit Care Med. 2020;48:e440–e469.
    1. Garritty C., Gartlehner G., Kamel C., King V.J., Nussbaumer-Streit B., Stevens A., et al. Cochrane rapid reviews. Interim guidance from the Cochrane rapid reviews methods Group. 2020. Available at: .
    1. Elliott J.H., Turner T., Clavisi O., Thomas J., Higgins J.P.T., Mavergames C., et al. Living systematic reviews: an emerging opportunity to narrow the evidence–practice gap. PLoS Med. 2014;11
    1. DerSimonian R., Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–114.
    1. Deeks J., Higgins J., Altman D. 2019. Cochrane handbook for systematic reviews of interventions [Internet] Available from:
    1. Hoy D., Brooks P., Woolf A., Blyth F., March L., Bain C., et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65:934–939.
    1. Arentz M., Yim E., Klaff L., Lokhandwala S., Riedo F.X., Chong M., et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA [Internet] 2020 [cited 2020 Apr 6]; Available from:
    1. Barrasa H., Rello J., Tejada S., Martin A., Balziskueta G., Vinuesa C., et al. SARS-Cov-2 in Spanish intensive care: early experience with 15-day survival in Vitoria. Anaesth Crit Care Pain Med. 2020 101652401.
    1. Bhatraju P.K., Ghassemieh B.J., Nichols M., Kim R., Jerome K.R., Nalla A.K., et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020 NEJMoa2004500.
    1. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy 2020 ((Su, Fu) School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China).
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
    1. Chen T, Dai Z, Mo P, Li X, Ma Z, Song S et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci 2020 (cba, 9502837).
    1. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med 2020 (9421642, bzs).
    1. Lian J., Jin X., Hao S., Cai H., Zhang S., Zheng L., et al. Analysis of epidemiological and clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis. 2020 (Jin, Gao, Ren) Department of Gastroenterology, First Affiliated Hospital, College of Medicine, Zhejiang University.
    1. Ling L., So C., Shum H.P., Chan P.K.S., Lai C.K.C., Kandamby D.H., et al. Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study. Crit Care Resusc J Australas Acad Crit Care Med. 2020 100888170.
    1. Liu W., Tao Z.-W., Lei W., Ming-Li Y., Kui L., Ling Z., et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020 (Ming) Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, China.
    1. Liu Y., Yang Y., Zhang C., Huang F., Wang F., Yuan J., et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364–374.
    1. Mo P., Xing Y., Xiao Y., Deng L., Zhao Q., Wang H., et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020 (Cheng) Department of Respiratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
    1. Pongpirul W.A., Mott J.A., Woodring J.V., Uyeki T.M., MacArthur J.R., Vachiraphan A., et al. Clinical characteristics of patients hospitalized with coronavirus disease, Thailand. Emerg Infect Dis. 2020;26
    1. Tan Y.-P., Tan B.-Y., Pan J., Wu J., Zeng S.-Z., Wei H.-Y. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. J Clin Virol. 2020:127. (Wu) Division of Pharmacy, College of Medicine, Hunan Normal University, Changsha 410005, China:104353.
    1. Wang L, He W, Yu X, Hu D, Bao M, Liu H et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020 ((Liu, Zhou) Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China).
    1. Wang Z., Yang B., Li Q., Wen L., Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020 (Yang) Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
    1. Wu C., Chen X., Cai Y., Xia J., Xu S., Huang H., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med [Internet] 2020 (Song) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China. Available from:
    1. Wu J., Li W., Shi X., Chen Z., Jiang B., Liu J., et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19) J Intern Med. 2020 (Cao) Zhejiang Provincial Key Laboratory for Diagnosis and Treatment of Aging and Physic-chemical Injury Diseases, 79 Qingchun Rd, Hangzhou 310003, China.
    1. Wu J., Liu J., Zhao X., Liu C., Wang W., Wang D., et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu Province: a multicenter descriptive study. Clin Infect Dis. 2020 (Cao) Zhejiang Provincial Key Laboratory for Diagnosis and Treatment of Aging and Physic-chemical Injury Diseases, Hangzhou, China.
    1. Xia W., Shao J., Guo Y., Peng X., Li Z., Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 ppul.24718.
    1. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med [Internet] 2020 (Yu) Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China. Available from:
    1. Young B.E., Ong S.W.X., Kalimuddin S., Low J.G., Tan S.Y., Loh J., et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA [Internet] 2020 (Chen, Lee, Leo) Saw Swee Hock School of Public Health, Singapore, Singapore. Available from:
    1. Zheng F., Liao C., Fan Q.-H., Chen H.-B., Zhao X.-G., Xie Z.-G., et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Curr Med Sci. 2020 (Zhong) Department of Pediatrics, Huazhong University of Science and Technology Hospital, Wuhan 430074, China.
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
    1. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020 (ig9, 7908424).
    1. Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020 ciaa530.
    1. Arabi Y.M., Deeb A.M., Al-Hameed F., Mandourah Y., Almekhlafi G.A., Sindi A.A., et al. Macrolides in critically ill patients with Middle East Respiratory Syndrome. Int J Infect Dis. 2019;81:184–190.
    1. Clancy C.J., Nguyen M.H. COVID-19, superinfections and antimicrobial development: what can we expect? Clin Infect Dis. 2020 ciaa524.
    1. Kumar A. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302:1872.
    1. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009;361:1925–1934.
    1. MacIntyre C.R., Chughtai A.A., Barnes M., Ridda I., Seale H., Toms R., et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza A(H1N1)pdm09. BMC Infect Dis. 2018;18:637.
    1. Memish Z.A., Perlman S., Van Kerkhove M.D., Zumla A. Middle East respiratory syndrome. Lancet. 2020;395:1063–1077.
    1. Kozak R., Prost K., Yip L., Williams V., Leis J.A., Mubareka S. Severity of coronavirus respiratory tract infections in adults admitted to acute care in Toronto, Ontario. J Clin Virol. 2020;126:104338.
    1. Chertow D.S., Memoli M.J. Bacterial coinfection in influenza: a grand rounds review. JAMA. 2013;309:275.
    1. National Institute for Health and Care Excellence (NICE) 2020. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital [Internet] Available from:
    1. Tamma P.D., Avdic E., Li D.X., Dzintars K., Cosgrove S.E. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177:1308.
    1. Buetti N., Mazzuchelli T., Lo Priore E., Balmelli C., Llamas M., Pallanza M., et al. Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. J Infect. 2020 S0163445320303819.
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel